Item 1.01
|
Entry into a Material Definitive Agreement.
|
Convertible Note Exchange
On February 24, 2020,
Endologix, Inc. (the Company) and three investors holding approximately $11.0 million of the principal amount of the Companys 3.25% Convertible Senior Notes due 2020 (the Holders)
entered into an Exchange Agreement (the Exchange Agreement) providing for the exchange of the Holders existing notes (the Existing Notes) for new 5.00% Voluntary Convertible Senior Notes due
2024 (the New Notes). Pursuant to the Exchange Agreement, on the date this Form 8-K is filed, the exchanging Holders are exchanging all outstanding principal plus accrued and unpaid
interest under the Existing Notes into the same amount of principal of New Notes pursuant to the Exchange Agreement (the Exchange). The New Notes are being issued in a transaction exempt from the registration requirements
of the Securities Act of 1933, as amended (the Securities Act) by virtue of Section 4(a)(2) of the Securities Act and Rule 506 thereunder.
The New Notes will be governed by an Indenture (the Indenture), by and between the Company and Wilmington Trust, National
Association, as trustee (the Trustee). The New Notes will accrue interest at a rate of 5.00% per year, payable semi-annually in arrears on April 1 and October 1 of each year, commencing April 1, 2020. The New
Notes will mature on April 2, 2024, unless earlier purchased, redeemed or converted in accordance with the terms of the Indenture. The Indenture governing the New Notes will contain customary terms and covenants and events of default.
The New Notes will be convertible at the option of each Holder into shares of common stock at any time prior to the close of business on the business day
immediately preceding January 1, 2024; provided that, except if the Company undergoes a fundamental change (as defined in the Indenture) and for certain other customary circumstances of conversion, each Holder may not convert more than 30% the
initial aggregate principal amount of its outstanding New Notes per calendar quarter (a Voluntary Conversion). Beginning January 1, 2024, until the close of business on the business day immediately preceding the
maturity date, the New Notes will be convertible at the option of the holder at any time regardless of the conditions described in this paragraph. The initial conversion rate of the New Notes in a Voluntary Conversion is 0.4445 shares of the
Companys common stock per $1.00 principal amount of the New Notes, which is equivalent to an initial conversion price per share equal to $2.25 (the Conversion Price). The conversion rate is subject to adjustment upon
the occurrence of certain specified events. Except if the Company undergoes a fundamental change (as defined in the Indenture) and for certain other customary circumstances of conversion, in no event prior to the close of business on the business
day immediately preceding January 1, 2024 may the New Notes be converted in a calendar quarter unless the closing sale price of the Companys common stock for at least twenty (20) trading days during the period of thirty
(30) consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 110% of the Conversion Price (subject to adjustment upon the occurrence of certain specified events) (the
Voluntary Conversion Threshold).
The New Notes will be secured by the Companys assets pursuant to a Junior Lien Security
Agreement by and between the Company and Wilmington Trust, National Association, as collateral agent (the JLSA). The JLSA grants a second lien on the Companys assets that is second in priority to the security
interests granted (i)_to Deerfield (as defined below), as agent, pursuant to the Amended and Restated Guaranty and Security Agreement, dated August 9, 2018, by and among Endologix, Inc., its subsidiaries and Deerfield, as agent, as amended to
date and (ii) to Deerfield ELGX Revolver, LLC, as agent (Deerfield ELGX), pursuant to the Guaranty and Security Agreement, dated as of August 9, 2018, by and among Endologix, Inc., its subsidiaries and Deerfield ELGX, as agent.
as amended to date. In connection with the issuance of the New Notes, the parties entered into Subordination and Intercreditor Agreement, dated as of February 24, 2020, by and among the Company, Deerfield, Deerfield ELGX and Wilmington Trust,
National Association, as collateral agent (the Subordination Agreement). The Subordination Agreement contains customary provisions associated with the subordination of the security interest of the New Notes.
The Indenture will provide that in no event may a Holder convert into shares of common stock if such conversion would result in the Holder beneficially owning
more that 9.5% of the Companys outstanding common stock. The foregoing descriptions of the terms of the Exchange Agreement, the Subordination Agreement, the Junior Security Agreement, the Indenture and the New Notes are qualified in their
entirety by reference to the text of such documents, copies of which are filed as Exhibits 10.1, 10.4, 10.5, 4.4 and 4.5 to this Current Report on Form 8-K.
Exchange Agreement and Fourth Amendment to Facility Agreement
On February 24, 2020, the Company entered into a February 2020 Exchange Agreement and Fourth Amendment to Amended and Restated Facility Agreement and
Amendment to First Out Waterfall Notes (the Facility Amendment) with Deerfield Private Design Fund IV, L.P. and certain other funds managed by Deerfield Management Company, L.P. (collectively,
Deerfield), dated August 9, 2018 (as amended to date, the Facility Agreement). The Facility Amendment provides for, among other things, the conversion of certain portions of the outstanding
convertible debt upon the achievement of certain milestones. In addition, 8.333% (or approximately $10.7 million as of February 24, 2020) of first out waterfall loans (the First Out Waterfall Loans) currently due
on April 2, 2021 (the First Amortization Payment) will be extended to July 1, 2021. In the event the Company satisfies the Initial Exchange Condition (as defined below) and provided that the Company reports net
revenue of at least $142.5 million for the year ended December 31, 2020 and complies with the global excess liquidity requirement (the Maturity Extension Conditions), the maturity date shall be extended from April 2,
2023 to December 22, 2023 and the second amortization date shall be extended from April 2, 2022 to April 2, 2023. Further, the Facility Amendment provides that the interest payment date due April 1, 2020 will be payable in paid-in-kind interest by increasing the principal amount of the loans by an amount equal to the interest that has accrued.